Filing Manager
Weiss Asset Management LP
Reporting Manager
Weiss Asset Management LP
Symbol
TBPH
Shares outstanding
51,428,000 shares
Disclosed Ownership
7,457,060 shares
Ownership
14%
Form type
SCHEDULE 13D/A
Filing time
25 Mar 2026, 16:05:02 UTC
Date of event
23 Mar 2026

Quoteable Key Fact

"Weiss Asset Management LP disclosed 14% ownership in Theravance Biopharma, Inc. Ordinary Share $0.00001 Par Value (TBPH) on 23 Mar 2026."

Quick Takeaways

  • Weiss Asset Management LP filed SCHEDULE 13D/A for Theravance Biopharma, Inc. Ordinary Share $0.00001 Par Value (TBPH).
  • Disclosed ownership: 14%.
  • Date of event: 23 Mar 2026.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 25 Mar 2026, 16:05.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (4)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Weiss Asset Management LP 14% 7,457,060 0 7,457,060 Mary Merrigan MARY MERRIGAN, AUTHORIZED SIGNATORY 0001357550
BIP GP LLC 9% 4,628,074 0 4,628,074 Mary Merrigan MARY MERRIGAN, AUTHORIZED SIGNATORY 0001298983
WAM GP LLC 14% 7,457,060 0 7,457,060 Mary Merrigan MARY MERRIGAN, AUTHORIZED SIGNATORY 0001504664
Andrew M. Weiss 14% 7,457,060 0 7,457,060 Mary Merrigan MARY MERRIGAN, ATTORNEY-IN-FACT FOR ANDREW M. WEISS*** 0001357643
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .